Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191022 · ClinicalTrials.gov registry record · Phase 2
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
A Phase 2 study of Social Phobia, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 15
- Study locations
NCT00191022 is a Phase 2 study of Social Phobia that has completed, run by Eli Lilly and Company. The registered enrollment target is 185 participants, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (45% higher). The trial reports 15 study locations across 13 states.
The verdict
NCT00191022, a Phase 2 study of Social Phobia, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.
Conditions Studied
Interventions
- DRUG placebo
- DRUG paroxetine
- DRUG LY686017
Study Locations (15)
California
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Burbank
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Newport Beach
Virginia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Herndon
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Richmond
Colorado
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Denver
Connecticut
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - New Britain
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Gainesville
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Indianapolis
Maryland
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Baltimore
Massachusetts
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191022
The ClinicalTrials.gov registry entry for NCT00191022 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (45% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Phobia appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00191022 reports 15 study locations spanning 13 distinct geographic areas - top geographies include California, Virginia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00191022 about?
NCT00191022 is a clinical study titled "Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder". This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.
What is the current status of trial NCT00191022?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2004-12. Estimated completion is 2007-01.
What conditions does trial NCT00191022 study?
This clinical trial studies the following conditions: Social Phobia.
What interventions are being tested in trial NCT00191022?
The interventions under investigation include: placebo (DRUG), paroxetine (DRUG), LY686017 (DRUG).
Who is sponsoring clinical trial NCT00191022?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00191022 being conducted?
This trial has 15 study locations across California, Colorado, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Phobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
COMPLETED · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
COMPLETED · Phase 2
-
Mindful Self-Compassion for Anxiety Disorders and Depression
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.